17 July 2017
The ADDRESS team, led by Professor Desmond Johnston at Imperial College London, have just published details of how they’re bringing people with Type 1 diabetes closer to cutting-edge research.
The After Diabetes Diagnosis REsearch Support System-2 (ADDRESS-2) is one project within the Type 1 diabetes Immunotherapy Consortium. The consortium is a UK-wide network of researchers studying new Type 1 diabetes immunotherapies, supported by Diabetes UK in partnership with Tesco and JDRF. Immunotherapies focus on retraining the immune system to prevent it from attacking the pancreas.
Building a Type 1 database and boosting recruitment
Since 2011, the ADDRESS team have built a database of data and biological samples from over 3,000 people with newly diagnosed Type 1 diabetes. This database is open-access, which means that researchers around the world can access the data and use it as a foundation for new studies.
ADDRESS-2 is also helping to meet the challenge of recruiting people with Type 1 diabetes to clinical trials in the UK. It helps researchers recruit the participants they need to carry out their vital work and pioneer new immunotherapies to prevent or reduce the impact of Type 1 diabetes.
By stimulating recruitment to trials and giving researchers access to important data, ADDRESS-2 aims to advance the development of new Type 1 diabetes treatments.
What to ADDRESS next?
ADDRESS researchers plan to use this information to study the genetics and biology behind the condition, alongside expanding their database and recruiting more people with Type 1 diabetes.
Dr Elizabeth Robertson, Director of Research at Diabetes UK said: “We’re hopeful that the Type 1 diabetes Immunotherapy Consortium, with support from Diabetes UK, will help us to find ways to prevent or reduce the progression of Type 1 diabetes. The ADDRESS team are leading the way in using open-access data to improve the lives of people with Type 1 diabetes, and these developments are only possible thanks to those who share their data and take part in research.”
You can find out more about ADDRESS-2 and how to get involved.